
The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group.

Results: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence. Methods: A retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations.


1Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czechia.Abanoub Riad 1, Ave Põld 2, Elham Kateeb 3,4 and Sameh Attia 5 *
